¼¼°èÀÇ ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀå
Diabetes Associated Ophthalmic Treatment
»óǰÄÚµå : 1779929
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 383 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,186,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,559,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀº 2030³â±îÁö 461¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 333¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 5.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 461¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ´ç´¢º´¼º ¾È°ú Ä¡·áÁ¦´Â CAGR 6.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 289¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ç´¢º´ ¾È°ú¿ë ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 91¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀº 2024³â¿¡ 91¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.0%¸¦ °ßÀÎÇϸç, 2030³â±îÁö 94¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.6%¿Í 5.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

´ç´¢º´°ú °ü·ÃµÈ ½Ã·Â Àå¾Ö´Â ¾î¶»°Ô ÀÀ±ÞÀÇ·á ¿ä±¸¸¦ »ý¼ºÇϴ°¡?

´ç´¢º´¼º ¸Á¸·Áõ, ´ç´¢º´¼º Ȳ¹ÝºÎÁ¾, ³ì³»Àå µî ´ç´¢º´°ú °ü·ÃµÈ ¾È°ú ÁúȯÀº Àü ¼¼°è¿¡¼­ ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Ç÷´çÀÌ Á¶ÀýµÇÁö ¾ÊÀ¸¸é ¸Á¸·ÀÇ ¼¶¼¼ÇÑ Ç÷°üÀÌ ¼Õ»óµÇ¾î ½Ã·ÂÀúÇϰ¡ ÁøÇàµÇ¾î ½ÉÇÑ °æ¿ì ½Ç¸í¿¡ À̸£°Ô µË´Ï´Ù. ƯÈ÷ °í·ÉÈ­ ¹× µµ½ÃÈ­ »çȸ¿¡¼­ÀÇ 2Çü ´ç´¢º´ À¯º´·ü Áõ°¡´Â ÷´Ü ¾È°ú Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ºÎÃß±â°í ÀÖ½À´Ï´Ù. ·¹ÀÌÀú ±¤ÀÀ°í¼ú°ú °°Àº ÀüÅëÀûÀÎ Ä¡·á¹ý ¿Ü¿¡µµ Ç×Ç÷°ü³»ÇǼºÀåÀÎÀÚ(anti-VEGF) ÁÖ»ç, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÀÓÇöõÆ® µî º¸´Ù Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ ½ÃÇàµÇ°í ÀÖÀ¸¸ç, ½Ã·Â À¯Áö¿¡ ÀÖÀ¸¸ç, Ä¡·á¼ºÀûÀÇ °³¼±ÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ºû°£¼·´ÜÃþÃÔ¿µ(OCT), ¾ÈÀúÃÔ¿µ µî ¿µ»ó Áø´Ü ±â¼úÀÇ º¸±ÞÀ¸·Î ´ç´¢º´¼º ¾ÈÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ´ç´¢º´ ¾È°ú ÀÇ·á¿¡ ´ëÇÑ Àνİú Á¤ºÎÀÇ ±¸»óÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ Àû½Ã¿¡ Ä¡·á¸¦ ¹ÞÀ¸·Á´Â °æÇâÀÌ ³ô¾ÆÁ® ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

´ç´¢º´ ȯÀÚ ¾È°ú Ä¡·áÀÇ Ãֽбâ¼ú Çõ½ÅÀº ¹«¾ùÀΰ¡?

´ç´¢º´ °ü·Ã ¾ÈÁúȯ Ä¡·á¹ýÀº »ý¹°Á¦Á¦, ÃÖ¼Òħ½À ¼ö¼ú ±â¼ú, ¼­¹æÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ µîÀÇ ¹ßÀüÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ¶ó´ÏºñÁÖ¸¿°ú ¾ÆÇø®¹ö¼ÁÆ®¿Í °°Àº Ç×VEGF »ý¹°Á¦Á¦ÀÇ µµÀÔÀº Ç÷°ü ´©ÃâÀ» °¨¼Ò½Ã۰í Áúº´ÀÇ ÁøÇàÀ» ¸·À½À¸·Î½á ´ç´¢º´¼º Ȳ¹ÝºÎÁ¾ °ü¸®¸¦ Å©°Ô °³¼±Çß½À´Ï´Ù. ¶ÇÇÑ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ±â¹Ý ¾È±¸³» ÀÓÇöõÆ®´Â ÀûÀº ÁÖ»ç Ƚ¼ö·Î Àå±âÀûÀÎ ¿ÏÈ­¸¦ °¡Á®¿À°í ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖÀ¸¸ç, Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ À¯¸Á Çõ½Å ºÐ¾ß´Â À¯ÀüÀÚ Ä¡·á·Î, Ç¥Àû À¯ÀüÀÚÀÇ º¯ÇüÀ» ÅëÇØ Á¤»óÀûÀÎ ¸Á¸· ±â´ÉÀ» ȸº¹½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¸Á¸· º¸Ã¶¹°À̳ª Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Àç»ý Ä¡·áÀÇ °³¹ßµµ ÁßÁõ ȯÀÚÀÇ ½Ã·Â ȸº¹À» À§ÇÑ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ¾È°ú¿¡¼­ ÀΰøÁö´É(AI)ÀÇ µîÀåÀº Ä¡·á °æ·Î¸¦ ´õ¿í ÃÖÀûÈ­Çϰí, ƯÈ÷ ½ºÅ©¸®´×°ú Á¶±â ¹ß°ß¿¡ ÀÖÀ¸¸ç, ÀÓ»ó °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ÀÇ·á±â±â ȸ»çµéÀÌ ¿¬±¸ ³ë·ÂÀ» °­È­ÇÏ´Â °¡¿îµ¥, ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·áÀÇ ¹Ì·¡´Â Á¡Á¡ ´õ À¯¸Á °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾È°ú ÀÇ·á Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇÑ ½ÃÀå ÇýÅÃÀº?

´ç´¢º´ ¾È°ú Ä¡·áÀÇ °¡Àå Å« º¯È­ Áß Çϳª´Â Á¤ºÎÀÇ ÇコÄÉ¾î ±¸»ó, º¸Çè Àû¿ë ¹üÀ§ È®´ë, ¿ø°ÝÀÇ·á ±â¼ú ¹ßÀü¿¡ ÈûÀÔ¾î Ä¡·á Á¢±Ù¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ Áø´Ü ÅøÀÌ 1Â÷ Áø·á ÇöÀå¿¡ ÅëÇÕµÇ¸é ´ç´¢¸Á¸·º´ÁõÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁ® Àü¹® ¾È°ú ¼¾ÅÍÀÇ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ À̵¿ ¾È°ú Áø·á¼Ò ¹× Áö¿ª »çȸ ºÀ»ç ÇÁ·Î±×·¥Àº ÀÇ·á ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â »ç¶÷µé¿¡°Ô °ËÁø ¹× Ä¡·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¾È°ú ½Ã¼ú ¹× ¾à¹° Ä¡·á¿¡ ´ëÇÑ º¸»ó Á¤Ã¥ÀÇ È®´ë´Â ´õ ¸¹Àº ȯÀÚµéÀÌ Àû½Ã¿¡ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ À¯º´·üÀÌ ºü¸£°Ô Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ±¹°¡¿¡¼­´Â ±¹Á¦ Çù·Â°ú ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ÷´Ü ¾È°ú Ä¡·á Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¿ë È¿À²ÀûÀÎ Ç× VEGF Ä¡·á¿ë ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ °³¹ß·Î Ä¡·áºñ¿ëÀÌ Àý°¨µÇ¾î ÃÖ÷´Ü Ä¡·á¹ýÀÌ º¸´Ù ³Î¸® º¸±ÞµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¼º Çâ»óÀº ´ç´¢º´ ȯÀÚÀÇ ¿¹¹æ °¡´ÉÇÑ ½Ç¸íÀ» ¾ïÁ¦ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº?

´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ´ç´¢º´ ºÎ´ã Áõ°¡, »ý¹°Á¦Á¦ äÅà Ȯ´ë, Á¶±â Áø´Ü ±â¼ú ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´¼º ¾ÈÁúȯ ¹ßº´ À§ÇèÀÌ ³ôÀº ³ëÀÎ Àα¸ Áõ°¡´Â ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼­¹æÇü ÀÓÇöõÆ® ¹× À¯ÀüÀÚ Ä¡·á¿Í °°Àº ¾à¹°Àü´ÞÀÇ Çõ½ÅÀº ȯÀÚÀÇ ¼øÀÀµµ¿Í ÀÓ»óÀû È¿°ú¸¦ Çâ»ó½ÃÄÑ »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾È°ú¿¡¼­ AIÀÇ µµÀÔÀÌ ÁøÇàµÊ¿¡ µû¶ó Á¶±â ¹ß°ßÀ²ÀÌ Çâ»óµÇ¾î º¸´Ù Àû±ØÀûÀÎ Ä¡·á Á¢±ÙÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ ¾È°ú ÀÇ·á Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Á¤ºÎ ÁÖµµÀÇ ÀÎ½Ä °³¼± ÇÁ·Î±×·¥ ¹× Á¤Ã¥ °³ÇõÀÌ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ¾È°ú ¼­ºñ½ºÀÇ È®´ë¿Í ¸ð¹ÙÀÏ Áø´Ü Ç÷§ÆûÀÇ º¸±ÞÀº ƯÈ÷ ³óÃ̰ú Àú¼Òµæ Áö¿ªÀÇ ÀÇ·á °ÝÂ÷¸¦ ÇØ¼ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à»çµéÀÇ ¾È°ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ È®´ë¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯ °æÀïÀÇ ºÎ»óÀ¸·Î ÷´Ü Ä¡·áÁ¦ÀÇ °¡°ÝÀÌ ´õ¿í Àú·ÅÇØÁ® ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´ç´¢º´ °ü·Ã ¾È°ú Ä¡·á ½ÃÀåÀº ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(´ç´¢º´ ¾È°ú Ä¡·áÁ¦, ´ç´¢º´ ¾È°ú Ä¡·á ±â±â), ¿ëµµ(´ç´¢¸Á¸·º´Áõ ¿ëµµ, ¾È±¸°ÇÁ¶Áõ ¿ëµµ, ³ì³»Àå ¿ëµµ, ´« ¾Ë·¹¸£±â¡¤°¨¿°Áõ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ¾È°ú ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ¿Ü·¡ ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diabetes Associated Ophthalmic Treatment Market to Reach US$46.1 Billion by 2030

The global market for Diabetes Associated Ophthalmic Treatment estimated at US$33.3 Billion in the year 2024, is expected to reach US$46.1 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diabetic Ophthalmic Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$28.9 Billion by the end of the analysis period. Growth in the Diabetic Ophthalmic Devices segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 9.0% CAGR

The Diabetes Associated Ophthalmic Treatment market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Diabetes Associated Ophthalmic Treatment Market - Key Trends & Drivers Summarized

How Is Diabetes-Linked Vision Impairment Creating Urgent Medical Needs?

Diabetes-associated ophthalmic conditions, including diabetic retinopathy, diabetic macular edema, and glaucoma, have become a growing concern due to the rising global prevalence of diabetes. Uncontrolled blood sugar levels damage the delicate blood vessels in the retina, leading to progressive vision loss and, in severe cases, blindness. The increasing incidence of type 2 diabetes, particularly in aging populations and urbanizing societies, has fueled the demand for advanced ophthalmic treatments. Conventional treatment approaches, such as laser photocoagulation, are now being supplemented by more innovative therapies, including anti-vascular endothelial growth factor (anti-VEGF) injections and corticosteroid implants, which have demonstrated improved outcomes in preserving vision. The growing accessibility of diagnostic imaging technologies, such as optical coherence tomography (OCT) and fundus photography, is enabling early detection and more effective management of diabetic eye diseases. Furthermore, with increasing awareness and government initiatives focusing on diabetic eye care, more patients are seeking timely treatment, driving the market forward.

What Are the Latest Innovations in Ophthalmic Treatments for Diabetic Patients?

The treatment landscape for diabetes-related eye diseases is undergoing a transformation, with advancements in biologics, minimally invasive surgical techniques, and sustained-release drug delivery systems. The introduction of anti-VEGF biologics, such as ranibizumab and aflibercept, has significantly improved the management of diabetic macular edema by reducing vascular leakage and halting disease progression. Additionally, corticosteroid-based intraocular implants are gaining popularity due to their ability to provide long-term relief with fewer injections, thereby improving patient compliance. Another promising area of innovation is gene therapy, which aims to restore normal retinal function through targeted genetic modifications. The development of retinal prosthetics and regenerative therapies, including stem cell-based interventions, is also opening new avenues for vision restoration in severe cases. The emergence of artificial intelligence (AI) in ophthalmology, particularly in screening and early detection, is further optimizing treatment pathways and improving clinical outcomes. With pharmaceutical and medical device companies intensifying research efforts, the future of diabetes-associated ophthalmic treatment looks increasingly promising.

How Is the Market Benefiting from Increased Accessibility to Eye Care?

One of the major shifts in diabetic eye care is the increased accessibility to treatment, driven by government healthcare initiatives, insurance coverage expansions, and technological advancements in telemedicine. The integration of AI-powered diagnostic tools into primary care settings allows for early identification of diabetic retinopathy, reducing the burden on specialized ophthalmology centers. Additionally, mobile eye care units and community outreach programs are playing a crucial role in bringing screening and treatment services to underserved populations. The expansion of reimbursement policies for ophthalmic procedures and drug therapies is further encouraging more patients to seek timely intervention. In emerging economies, where diabetes prevalence is rising rapidly, international collaborations and public-private partnerships are enhancing access to advanced ophthalmic treatments. Furthermore, the development of cost-effective biosimilars for anti-VEGF therapies is expected to reduce treatment costs, making cutting-edge care more widely available. These improvements in accessibility are playing a pivotal role in curbing preventable blindness among diabetic populations.

What Are the Key Growth Drivers of the Diabetes-Associated Ophthalmic Treatment Market?

The growth in the diabetes-associated ophthalmic treatment market is driven by several factors, including the rising global diabetes burden, increasing adoption of biologic therapies, and advancements in early diagnostic technologies. The growing geriatric population, which is at a higher risk of developing diabetic eye diseases, is significantly contributing to market expansion. Innovations in drug delivery, such as sustained-release implants and gene therapy, are improving patient adherence and clinical efficacy, further boosting demand for novel treatments. The increasing deployment of AI in ophthalmology is also enhancing early detection rates, leading to more proactive treatment approaches. Additionally, government-led awareness programs and policy reforms aimed at improving eye care accessibility are playing a crucial role in market growth. The expansion of teleophthalmology services and the proliferation of mobile diagnostic platforms are bridging healthcare gaps, particularly in rural and low-income regions. Moreover, the growing investments by pharmaceutical companies in ophthalmic R&D and the rise of biosimilar competition are making advanced treatments more affordable, fueling further market expansion. With continuous innovation and increasing patient awareness, the diabetes-associated ophthalmic treatment market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetes Associated Ophthalmic Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Diabetic Ophthalmic Drugs, Diabetic Ophthalmic Devices); Application (Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy and Infection Application, Other Applications); End-Use (Hospitals End-Use, Ophthalmic Centers End-Use, Ambulatory Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â